Asia-Pacific

In India, PATH uses digital technology to initiate early treatment and improve the TB care cascade.

In India, PATH is engaging with private health care providers to advance India’s digital health mission.

Japanese encephalitis (JE) is the leading viral cause of disability in Asia. The mosquitoes that transmit JE breed in areas of standing water, such as rice paddies, making rural communities of Asia particularly vulnerable. Immunization is the best method to prevent JE, but control efforts have been hindered by inadequate disease surveillance, limited/unstable vaccine supply, variable guidance and programmatic support, and competing country/state priorities. Over the past several years, focused efforts from PATH and other partners have improved the landscape of JE control across the country.In 2006, the government launched the Japanese Encephalitis Vaccine (JEV) campaign, rolling out a successful program within eight months. Over nine million children were able to receive JEV ahead of the JE season in India. This proved to be a landmark year for India’s rural population after decades of suffering from recurring JE outbreaks.This document details the phased JEV campaign across select endemic districts of Bihar, followed by the introduction of JEV in the routine immunization schedule and the lessons learned for strengthening immunization program all across.

Listed are a web page and fact sheet (Chinese and English translations) summarizing and linking to the offerings included in a training series developed by PATH entitled "Global Access Training for Chinese COVID-19 Vaccine Developers." The training is designed to provide an overview of key vaccine development strategies and planning necessary to develop COVID-19 vaccines that meet World Health Organization prequalification requirements and are competitive in the global market.

Healthy Markets, an eight-year initiative funded by PEPFAR through USAID and implemented by PATH, aimed to grow a viable commercial market for HIV-related products and services in Vietnam. Through applying a total market approach and responding to key population health care needs through innovation, Healthy Markets contributed to improved sustainability and country ownership of the HIV response and supported the government of Vietnam in advancing toward HIV epidemic control by 2030. This report presents key results, impact, and learnings from the project.

During the Union World Conference on Lung Health 2022, PATH will showcase our continued commitment to advancing TB care through patient-centered innovations and systems-level advancements.

The Vietnam Ministry of Health and USAID through its supported project, PATH STEPS, outlined an implementation road map for Vietnam’s first-ever HIV private-sector engagement plan

The purpose of this action brief is to review and discuss the current situation of Hepatitis-C Virus (HCV) among People Who Inject Drugs (PWID) in India. Further, this action brief would provide potential strategies in strengthening HCV screening, confirmatory testing, treatment initiation, and treatment completion among PWIDs in India.

Diagnostics are fundamental to accurate detection of disease and critical to informing effective clinical care and selection of treatment. Yet access to diagnostic testing has remained poor and inequitable in many parts of the world. Approximately 47 percent of the global population has little to no access to diagnostics. This challenge is particularly evident in low- and middle-income countries, where only 19 percent of patients have access to appropriate diagnostics at the primary health care level.To develop this report, PATH collaborated with Accenture to investigate access challenges within the diagnostics ecosystems in Latin America, Africa, and Southeast Asia to identify market failures and market-shaping interventions needed for LMICs and close the existing diagnostics gap. The report highlights existing market failures across the diagnostics value chain and provides recommendations for expanded access to quality diagnostics in low- and middle-income countries.Click here to view an interactive dashboard of diagnostic companies with a manufacturing presence based in Africa, Latin America, and Southeast Asia.